Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Comprehensive Overview
Published in Nature in 2017, this first-in-human study asked whether a vaccine custom-built from a patient's own tumor mutations could train the immune system to recognize and attack melanoma, a strategy long theorized but never tested in people. Cancer cells accumulate mutations that create abnormal proteins, called neo-epitopes, which the immune system can potentially learn to recognize as foreign; because these mutations differ from patient to patient, researchers designed a fully individualized vaccine for each participant, encoding up to ten of that patient's own mutations into a single RNA molecule. To build each vaccine, researchers sequenced a patient's tumor to find its mutations, then used computer algorithms to predict which mutated proteins the patient's own immune system was most likely to recognize. Thirteen patients with high-risk, surgically treated stage III or IV melanoma received between eight and twenty doses of their personalized vaccine, injected directly into lymph nodes over several months, while researchers monitored immune responses and tracked recurrence for up to two years. The topline result was that every vaccinated patient developed new immune T cells against multiple of their own tumor mutations, and two patients with active metastatic disease experienced measurable tumor shrinkage directly attributable to the vaccine.
Outcomes and Implications
The single most important finding was that every one of the thirteen vaccinated patients developed new immune T cells recognizing their own tumor mutations, with 60 percent of the 125 targeted mutations provoking a detectable response and each patient mounting immunity against at least three distinct mutations. These vaccine-induced T cells were shown to infiltrate patients' actual tumors and kill tumor cells in laboratory testing, and after vaccination began, the rate at which patients developed new metastases dropped sharply, translating into sustained periods without disease progression. Two patients who still had measurable tumors when vaccination started saw their metastases shrink, one to complete disappearance when the vaccine was combined with radiation and an antibody drug called ipilimumab, and researchers cautioned that this benefit could not be attributed to the vaccine alone. A third patient initially relapsed with tumor cells that had lost the very molecular machinery needed to display mutations to the immune system, a well-known escape mechanism, but combining the vaccine with a checkpoint-blocking antibody, pembrolizumab, produced a complete response. Patients tolerated up to twenty vaccine doses with no related serious side effects reported. For melanoma patients at high risk of recurrence after surgery, where options beyond surveillance remain limited, these findings suggest that individually tailored, mutation-specific vaccines can safely mobilize a broad, personalized immune attack on cancer and may work best when paired with existing immunotherapies that help overcome the tumor's own resistance strategies.